Omnia Education

Omnia Education

By ReachMDMedicine
Download on the App Store

Omnia Education episodes

  • The Alloimmune Disorders of Pregnancy
    Guest: Karin J. Blakemore, MD
    Guest: Emilie L. Vander Haar

    Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

    4 min
  • Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT): The Platelet Equivalent of Rh Disease
    Guest: Karin J. Blakemore, MD
    Guest: Emilie L. Vander Haar

    Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

    6 min
  • Classification/Suspecting a Diagnosis of FNAIT/NAIT
    Guest: Karin J. Blakemore, MD
    Guest: Emilie L. Vander Haar

    Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

    5 min
  • Current Diagnostic Signs, Symptoms, and Lab Tests for FNAIT
    Guest: Karin J. Blakemore, MD
    Guest: Emilie L. Vander Haar

    Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

    5 min
  • Current Management Strategies for FNAIT
    Guest: Karin J. Blakemore, MD
    Guest: Emilie L. Vander Haar

    Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

    5 min
  • Managing the “Next Pregnancy” in Patients With an FNAIT-Affected First Child
    Guest: Karin J. Blakemore, MD
    Guest: Emilie L. Vander Haar

    Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

    6 min
  • Screening for FNAIT: Anticipating HPA-1a Incompatibility
    Guest: Karin J. Blakemore, MD
    Guest: Emilie L. Vander Haar

    Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

    5 min
  • Neonatal FcRn Inhibition: A New Pathway for Addressing the Alloimmune Disorders of Pregnancy
    Guest: Karin J. Blakemore, MD
    Guest: Emilie L. Vander Haar

    Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

    4 min
  • Nipocalimab: An FcRn Inhibitor and Its Role in Treating HDFN
    Guest: Karin J. Blakemore, MD
    Guest: Emilie L. Vander Haar

    Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

    5 min
  • Key Patient Counseling Issues Surrounding FNAIT and Its Risk in Subsequent Pregnancies
    Guest: Karin J. Blakemore, MD
    Guest: Emilie L. Vander Haar

    Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

    5 min

About Omnia Education

From the publisher's feed

Omnia Education is exclusively focused on women’s health and the ways in which diseases and conditions impact the female patient. That unique focus on the female patient has allowed Omnia Education to…